Clinical Trials Browser

Phase 2 × Breast Neoplasms × tislelizumab × Clear all

NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms